Natural history, risk factors and management of hepatitis C after liver transplantation

Research output: Contribution to journalArticle

Abstract

Recurrent HCV is universal after liver transplantation in patients viremic at the time of transplantation and leads to cirrhosis in up to 30% of patients by five years. This has led to recurrent HCV emerging as an important yet controversial indication for liver retransplantation. Despite encouraging results with pegylated interferon and ribavirin therapy in the non-transplant HCV population, these findings have not translated to transplant recipients where viral eradication is frequently unsuccessful largely due to drug intolerance. The lack of effective therapies, severe side effects and reports of hepatic decompensation despite HCV eradication raises the question of whether recurrent HCV genotype 1 should be treated with interferon-based therapies. Although protease inhibitors were recently approved for the treatment of genotype1 HCV patients in combination with pegylated interferon and ribavirin, these new agents are contraindicated in liver transplant patients due to severe drug toxicity.

Original languageEnglish
Pages (from-to)124-130
Number of pages7
JournalInflammation and Allergy - Drug Targets
Volume11
Issue number2
StatePublished - Apr 2012
Externally publishedYes

Fingerprint

Risk Management
Hepatitis C
Natural History
Liver Transplantation
Interferons
Ribavirin
Liver
Therapeutics
Protease Inhibitors
Drug-Related Side Effects and Adverse Reactions
Fibrosis
Transplantation
Genotype
Transplants
Pharmaceutical Preparations
Population

All Science Journal Classification (ASJC) codes

  • Immunology
  • Immunology and Allergy
  • Pharmacology

Cite this

Natural history, risk factors and management of hepatitis C after liver transplantation. / Mukherjee, Sandeep.

In: Inflammation and Allergy - Drug Targets, Vol. 11, No. 2, 04.2012, p. 124-130.

Research output: Contribution to journalArticle

@article{0562d41bc3314eb8bac20678a5504498,
title = "Natural history, risk factors and management of hepatitis C after liver transplantation",
abstract = "Recurrent HCV is universal after liver transplantation in patients viremic at the time of transplantation and leads to cirrhosis in up to 30{\%} of patients by five years. This has led to recurrent HCV emerging as an important yet controversial indication for liver retransplantation. Despite encouraging results with pegylated interferon and ribavirin therapy in the non-transplant HCV population, these findings have not translated to transplant recipients where viral eradication is frequently unsuccessful largely due to drug intolerance. The lack of effective therapies, severe side effects and reports of hepatic decompensation despite HCV eradication raises the question of whether recurrent HCV genotype 1 should be treated with interferon-based therapies. Although protease inhibitors were recently approved for the treatment of genotype1 HCV patients in combination with pegylated interferon and ribavirin, these new agents are contraindicated in liver transplant patients due to severe drug toxicity.",
author = "Sandeep Mukherjee",
year = "2012",
month = "4",
language = "English",
volume = "11",
pages = "124--130",
journal = "Current Drug Targets: Inflammation and Allergy",
issn = "1871-5281",
publisher = "Bentham Science Publishers B.V.",
number = "2",

}

TY - JOUR

T1 - Natural history, risk factors and management of hepatitis C after liver transplantation

AU - Mukherjee, Sandeep

PY - 2012/4

Y1 - 2012/4

N2 - Recurrent HCV is universal after liver transplantation in patients viremic at the time of transplantation and leads to cirrhosis in up to 30% of patients by five years. This has led to recurrent HCV emerging as an important yet controversial indication for liver retransplantation. Despite encouraging results with pegylated interferon and ribavirin therapy in the non-transplant HCV population, these findings have not translated to transplant recipients where viral eradication is frequently unsuccessful largely due to drug intolerance. The lack of effective therapies, severe side effects and reports of hepatic decompensation despite HCV eradication raises the question of whether recurrent HCV genotype 1 should be treated with interferon-based therapies. Although protease inhibitors were recently approved for the treatment of genotype1 HCV patients in combination with pegylated interferon and ribavirin, these new agents are contraindicated in liver transplant patients due to severe drug toxicity.

AB - Recurrent HCV is universal after liver transplantation in patients viremic at the time of transplantation and leads to cirrhosis in up to 30% of patients by five years. This has led to recurrent HCV emerging as an important yet controversial indication for liver retransplantation. Despite encouraging results with pegylated interferon and ribavirin therapy in the non-transplant HCV population, these findings have not translated to transplant recipients where viral eradication is frequently unsuccessful largely due to drug intolerance. The lack of effective therapies, severe side effects and reports of hepatic decompensation despite HCV eradication raises the question of whether recurrent HCV genotype 1 should be treated with interferon-based therapies. Although protease inhibitors were recently approved for the treatment of genotype1 HCV patients in combination with pegylated interferon and ribavirin, these new agents are contraindicated in liver transplant patients due to severe drug toxicity.

UR - http://www.scopus.com/inward/record.url?scp=84857769402&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857769402&partnerID=8YFLogxK

M3 - Article

VL - 11

SP - 124

EP - 130

JO - Current Drug Targets: Inflammation and Allergy

JF - Current Drug Targets: Inflammation and Allergy

SN - 1871-5281

IS - 2

ER -